The company Harmonium Innovation has concluded the project "Research and development of new solutions for biofunctional textile garments", with code 08/2020, thanks to the help of the ICEX of the Ministry of Industry, Trade and Tourism, co-financed by the European Union (FEDER Funds) to through the Investment Program for foreign companies in R&D activities.
This project began in March 2020, when the key strategic objective of developing a unique product capable of leading the prevention and early treatment of diabetic foot, with sufficient differential value, was proposed to allow Harmonium Innovation to lead this market. As well as, obtain an innovative biofunctional product (girdle, pantyhose) for the treatment of localized fat that allows to differentiate itself from the rest of the competition, having a differential competitive advantage that allows a better position in this new market niche that the company intends to access .
In general, HARMONIUM INNOVATION, with this project has pursued the development of a stable technological platform in the transversal development of biofunctional textile garments especially for the treatment and prevention of diabetic foot and obesity, based on technologies of electromagnetic wavelengths and transdermal transfer nanoparticles. With this, a combined technology will be obtained, a pioneering and disruptive fact in the sector, which will serve as the basis for the future development of new products for health and well-being.
After 10 months of work, the company has achieved the strategic challenge sought.
About Harmonium Innovation
Harmonium Innovation is a Research & Development Healthcare company based in the Canary Islands with a headquarters in United Kingdom, partially owned by Harmonium Investments, which offers innovative healthcare solutions for millions of people worldwide.
Harmonium Innovation is a new company focused on the research and development of new innovative products and patents with a major focus on diabetes, with the objective of international commercialization of it´s complete product range.
This process, controlled by Harmonium Innovation, guarantees a continued innovative product portfolio's growth and constant improvement of offered solutions.
In Harmonium Innovation, We have a unique way of building strong international relationships, offering not only a complete product range, which responds to the need of millions of people worldwide, but also helping our international Partners to reach their objectives. We explain them a know-how of our company and support them in all the time of our relationship.
And the most important, we help our Customers meet their increasingly growing needs with our innovative solutions, and we make them feel confident.
Our Values
Our Pipeline
Diabetes
Oncology
Cardiometabolic Disease
Digital
Health
Therapeutic
Clothing
Chronic
Pain
Nervous System Diseases
Our Objectives
Become Our Partner
Meet Our Team
Fernando Rueda
Founder and Executive Chairman In Harmonium Innovation
& CEO Spain/Portugal Harmonium Pharma Ibérica
More than 30 years experience in sales and business development in the pharmaceutical industry.
Specialized in cardio-metabolic diseases and diabetes. Since 2012, he led many projects related with the pharmaceutical industry. His projects are mainly oriented towards diabetes, and chronicle patients.
Work experience in major pharmaceutical corporations
such as, Bristol Myers, Sanofi Aventis, ...
Ugo Cosentino
Founder and CEO of Harmonium Group
.
More than 26 years experience in financial and general management in different countries
(Italy, France, UK, Netherlands), in the pharmaceutical industry.
Founder and owner of Harmonium Pharma, a London based pharmaceutical company with offices in Italy and France.
Work experience as European President for Wyeth & President and CEO of
Pfizer Italy.
Our Strategic Partners
Our Investors
Harmonium Investment,
Ltd. UK
Iniciativas de Valor Añadido,
S.L. Spain
Harmonium Innovation´s Blog
Where We Are
We are located in the Innovation and Technology Park of ULPGC University.
